Dasatinib first-line treatment in gastrointestinal stromal tumors: A multicenter phase II trial of the SAKK (SAKK 56/07).
Michael Montemurro
Honoraria - Bayer; Novartis; Pfizer
Julien Domont
No relevant relationships to disclose
Aurore Blesius
No relevant relationships to disclose
Piotr Rutkowski
Honoraria - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Arnaud Roth
No relevant relationships to disclose
Roger Von Moos
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme (U); Novartis; Pfizer; Roche
Honoraria - Amgen; Roche
Research Funding - Amgen; Roche
Expert Testimony - Amgen (U)
Roman Ignaz Inauen
No relevant relationships to disclose
Binh Bui Nguyen
Honoraria - Novartis; PharmaMar
Roger Burkhard
No relevant relationships to disclose
Claudio Knusli
No relevant relationships to disclose
Sebastian Bauer
Honoraria - Bristol-Myers Squibb
Philippe A Cassier
No relevant relationships to disclose
Heike Schwarb
No relevant relationships to disclose
Axel Le Cesne
Honoraria - Novartis; Pfizer; PharmaMar
Dieter Koeberle
No relevant relationships to disclose
Vincent Dunet
No relevant relationships to disclose
Daniel Dietrich
No relevant relationships to disclose
Christine Biaggi
No relevant relationships to disclose
John Prior
No relevant relationships to disclose
Serge Leyvraz
No relevant relationships to disclose